AU2002305706A1 - Use of tripeptide gpe for treating or preventing symptoms of parkinson's disease - Google Patents

Use of tripeptide gpe for treating or preventing symptoms of parkinson's disease

Info

Publication number
AU2002305706A1
AU2002305706A1 AU2002305706A AU2002305706A AU2002305706A1 AU 2002305706 A1 AU2002305706 A1 AU 2002305706A1 AU 2002305706 A AU2002305706 A AU 2002305706A AU 2002305706 A AU2002305706 A AU 2002305706A AU 2002305706 A1 AU2002305706 A1 AU 2002305706A1
Authority
AU
Australia
Prior art keywords
parkinson
disease
treating
preventing symptoms
gpe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002305706A
Inventor
Peter D. Gluckman
Jian Guan
Rita V. M. Krishnamurthi
Christopher E. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuronz Ltd
Original Assignee
Neuronz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronz Ltd filed Critical Neuronz Ltd
Publication of AU2002305706A1 publication Critical patent/AU2002305706A1/en
Abandoned legal-status Critical Current

Links

AU2002305706A 2001-05-24 2002-05-23 Use of tripeptide gpe for treating or preventing symptoms of parkinson's disease Abandoned AU2002305706A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/866,536 2001-05-24

Publications (1)

Publication Number Publication Date
AU2002305706A1 true AU2002305706A1 (en) 2002-12-03

Family

ID=

Similar Documents

Publication Publication Date Title
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
AU2002319615A1 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2002246490A1 (en) Method of treating parkinson's disease
AU2003268295A1 (en) "diagnosis and treatment of infertility"
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2003248893A1 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias
AU2002305706A1 (en) Use of tripeptide gpe for treating or preventing symptoms of parkinson's disease
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
PL362869A1 (en) Use of chromanes for treating parkinson's disease
AU2003286530A1 (en) Substituted peptides useful in the treatment of alzheimer's disease
AU2003277298A1 (en) Pharmaceutical compositions for treatment of parkinson's disease
AU2002235924A1 (en) Cyp46 genotype determination for risk and treatment evaluation of alzheimer's disease
AU2002219231A1 (en) Use of chromanes for treating parkinson's disease
AU2002316622A1 (en) Aminediols for the treatment of alzheimer's disease
AU2002320537A1 (en) Diaminediols for the treatment of alzheimer's disease